Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies

US10444242B2 · kind B2 · utility

Assignees

• Abbott Laboratories · US
• ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · US

Inventors

• Robert N. Ziemann · Palatine, US
• April Ahlberg · Libertyville, US
• David J. Hawksworth · Vernon Hills, US
• Bryan C. Tieman · Libertyville, US
• A. Scott Muerhoff · Kenosha, US
• Christopher Marohnic · Libertyville, US
• Kathy Otis · Libertyville, US
• Andrea Branch · New York, US
• Francis Eng · New York, US

Key dates

• Filing date: Jun 22, 2016
• Grant date: Oct 15, 2019
• Expiry date: Jul 16, 2036

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/52
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.